Disopyramide and Revumenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Disopyramide
Revumenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Avoid concomitant use of revumenib and drugs known to prolong the QTc interval, as it may increase the risk of QT interval prolongation. Correct electrolyte abnormalities prior treatment with revumenib. Perform an ECG at least once a week for the first 4 weeks on treatment, and at least monthly thereafter. Interrupt revumenib if QTcF increases to greater than 480 msec and less than 500 msec, and restart revumenib at the same dose twice daily after the QTcF interval returns to less than or equal to 480 msec. Interrupt revumenib if QTcF increases to greater than 500 msec or greater than 60 msec from baseline, and restart revumenib twice daily at the lower dose level after the QTcF interval returns to less than or equal to 480 msec. Permanently discontinue revumenib in patients with ventricular arrhythmias and in those who develop QTc interval prolongation with signs or symptoms of life threatening arrhythmia1.
Why it happens (mechanism)
Additive QT interval prolongation
Literature reports
1 report — tap to read
a) In the clinical trials, QTc interval prolongation was reported as an adverse reaction in 39 (29%) of 135 patients treated with revumenib at the recommended dosage for relapsed or refractory acute leukemia with a KMT2A translocation; QTc interval prolongation was Grade 3 in 12%. The heart-rate corrected QT interval (using Fridericia’s method) (QTcF) was greater than 500 msec in 8%, and the increase from baseline QTcF was greater than 60 msec in 18%. revumenib dose reduction was required for 5% due to QTc interval prolongation. QTc prolongation occurred in 16% of the 31 patients less than 17 years old, 33% of the 88 patients 17 years to less than 65 years old, and in 50% of the 16 patients 65 years or older 1.
Common questions
Can I take Disopyramide and Revumenib together?
An increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Disopyramide and Revumenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Disopyramide or Revumenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: REVUFORJ oral tablets, revumenib oral tablets. Syndax Pharmaceuticals, Inc. (per FDA), Waltham, MA, 2024. DailyMed
Keep reading about Disopyramide
Keep reading about Revumenib
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist